Literature DB >> 29760049

Insulin suppresses the production of fibroblast growth factor 23 (FGF23).

Ludmilla Bär1, Martina Feger1, Abul Fajol2, Lars-Oliver Klotz3, Shufei Zeng4,5, Florian Lang6, Berthold Hocher4,5, Michael Föller7.   

Abstract

Fibroblast growth factor 23 (FGF23) is produced by bone cells and regulates renal phosphate and vitamin D metabolism, as well as causing left ventricular hypertrophy. FGF23 deficiency results in rapid aging, whereas high plasma FGF23 levels are found in several disorders, including kidney or cardiovascular diseases. Regulators of FGF23 production include parathyroid hormone (PTH), calcitriol, dietary phosphate, and inflammation. We report that insulin and insulin-like growth factor 1 (IGF1) are negative regulators of FGF23 production. In UMR106 osteoblast-like cells, insulin and IGF1 down-regulated FGF23 production by inhibiting the transcription factor forkhead box protein O1 (FOXO1) through phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB)/Akt signaling. Insulin deficiency caused a surge in the serum FGF23 concentration in mice, which was reversed by administration of insulin. In women, a highly significant negative correlation between FGF23 plasma concentration and increase in plasma insulin level following an oral glucose load was found. Our results provide strong evidence that insulin/IGF1-dependent PI3K/PKB/Akt/FOXO1 signaling is a powerful suppressor of FGF23 production in vitro as well as in mice and in humans.

Entities:  

Keywords:  Klotho; PI3K; PKB/Akt; phosphate

Mesh:

Substances:

Year:  2018        PMID: 29760049      PMCID: PMC5984514          DOI: 10.1073/pnas.1800160115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Authors:  Serge L Ferrari; Jean-Philippe Bonjour; René Rizzoli
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  PKB/SGK-resistant GSK3 enhances phosphaturia and calciuria.

Authors:  Michael Föller; Daniela S Kempe; Krishna M Boini; Ganesh Pathare; Balasaheb Siraskar; Paola Capuano; Ioana Alesutan; Mentor Sopjani; Gerti Stange; Nilufar Mohebbi; Madhuri Bhandaru; Teresa F Ackermann; Martin S Judenhofer; Bernd J Pichler; Jürg Biber; Carsten A Wagner; Florian Lang
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

3.  Soluble klotho binds monosialoganglioside to regulate membrane microdomains and growth factor signaling.

Authors:  George Dalton; Sung-Wan An; Saif I Al-Juboori; Nicole Nischan; Joonho Yoon; Evgenia Dobrinskikh; Donald W Hilgemann; Jian Xie; Kate Luby-Phelps; Jennifer J Kohler; Lutz Birnbaumer; Chou-Long Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

4.  Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B.

Authors:  G Rena; S Guo; S C Cichy; T G Unterman; P Cohen
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

Review 5.  FGF23-αKlotho as a paradigm for a kidney-bone network.

Authors:  Makoto Kuro-O; Orson W Moe
Journal:  Bone       Date:  2016-11-12       Impact factor: 4.398

6.  Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients.

Authors:  Kristian Winther; Mads Nybo; Birgitte Vind; Susanne Møller Pedersen; Kurt Højlund; Lars Melholt Rasmussen
Journal:  Scand J Clin Lab Invest       Date:  2011-12-01       Impact factor: 1.713

Review 7.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

Review 8.  Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.

Authors:  Peter Kamenický; Gherardo Mazziotti; Marc Lombès; Andrea Giustina; Philippe Chanson
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

9.  1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6.

Authors:  Rimpi K Saini; Ichiro Kaneko; Peter W Jurutka; Ryan Forster; Antony Hsieh; Jui-Cheng Hsieh; Mark R Haussler; G Kerr Whitfield
Journal:  Calcif Tissue Int       Date:  2012-12-22       Impact factor: 4.333

Review 10.  FGF23 in Acute and Chronic Illness.

Authors:  Christian Schnedl; Astrid Fahrleitner-Pammer; Peter Pietschmann; Karin Amrein
Journal:  Dis Markers       Date:  2015-09-28       Impact factor: 3.434

View more
  36 in total

1.  p38MAPK controls fibroblast growth factor 23 (FGF23) synthesis in UMR106-osteoblast-like cells and in IDG-SW3 osteocytes.

Authors:  F Ewendt; M Föller
Journal:  J Endocrinol Invest       Date:  2019-06-14       Impact factor: 4.256

Review 2.  New concepts in regulation and function of the FGF23.

Authors:  Sanaz Dastghaib; Farhad Koohpeyma; Mesbah Shams; Forough Saki; Aliakbar Alizadeh
Journal:  Clin Exp Med       Date:  2022-06-16       Impact factor: 3.984

Review 3.  Regulation of FGF23: Beyond Bone.

Authors:  Petra Simic; Jodie L Babitt
Journal:  Curr Osteoporos Rep       Date:  2021-11-10       Impact factor: 5.096

4.  Fibroblast Growth Factor 23 and Cardiovascular Risk in Diabetes Patients-Cardiologists Be Aware.

Authors:  Anna Kurpas; Karolina Supel; Paulina Wieczorkiewicz; Joanna Bodalska Duleba; Marzenna Zielinska
Journal:  Metabolites       Date:  2022-05-30

5.  Kidney to bone via bedside to bench…and back?

Authors:  Alexander Grabner; Myles Wolf
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 6.  Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions.

Authors:  L Darryl Quarles
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-01       Impact factor: 2.894

7.  Peroxisome proliferator-activated receptor α (PPARα)-dependent regulation of fibroblast growth factor 23 (FGF23).

Authors:  Franz Ewendt; Frank Hirche; Martina Feger; Michael Föller
Journal:  Pflugers Arch       Date:  2020-03-18       Impact factor: 3.657

8.  Orphan nuclear receptor ERR-γ regulates hepatic FGF23 production in acute kidney injury.

Authors:  Kamalakannan Radhakrishnan; Yong-Hoon Kim; Yoon Seok Jung; Don-Kyu Kim; Soon-Young Na; Daejin Lim; Dong Hun Kim; Jina Kim; Hyung-Seok Kim; Hyon E Choy; Sung Jin Cho; In-Kyu Lee; Şamil Ayvaz; Stefanie Nittka; Danilo Fliser; Stefan J Schunk; Thimoteus Speer; Steven Dooley; Chul-Ho Lee; Hueng-Sik Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

9.  Myostatin regulates the production of fibroblast growth factor 23 (FGF23) in UMR106 osteoblast-like cells.

Authors:  Franz Ewendt; Martina Feger; Michael Föller
Journal:  Pflugers Arch       Date:  2021-04-25       Impact factor: 3.657

Review 10.  FGF23, Biomarker or Target?

Authors:  Cristian Rodelo-Haad; Rafael Santamaria; Juan R Muñoz-Castañeda; M Victoria Pendón-Ruiz de Mier; Alejandro Martin-Malo; Mariano Rodriguez
Journal:  Toxins (Basel)       Date:  2019-03-22       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.